Literature DB >> 15777546

Non-high density lipoprotein cholesterol is the best discriminator of myocardial infarction in young individuals.

Loukianos S Rallidis1, Christos Pitsavos, Demosthenes B Panagiotakos, Loukas Sinos, Christodoulos Stefanadis, Dimitrios T Kremastinos.   

Abstract

BACKGROUND: Several studies have shown that non-high density lipoprotein (HDL) cholesterol is a strong and independent predictor of cardiovascular events. We investigated whether non-HDL cholesterol can discriminate young individuals with myocardial infarction (MI) from age- and sex-matched controls.
METHODS: We conducted a case-control study which included 100 consecutive patients who had survived their first MI before the age of 36 years and 100 age- and sex-matched healthy controls without a history of cardiovascular disease. Cardiovascular risk factors were reported and fasting lipids and apolipoproteins were measured.
RESULTS: Patients with premature MI had significantly higher levels of total cholesterol, low density lipoprotein cholesterol, triglycerides, apolipoprotein B, lipoprotein (a) and non-HDL cholesterol and significantly lower levels of HDL cholesterol and apolipoprotein A. Multivariate logistic regression analysis showed that for every 10mg/dl increase in non-HDL cholesterol levels, the odds of having a MI were increased by 34% after controlling for age, sex, body mass index, presence of hypertension, diabetes and smoking habits. Moreover, participants in the highest tertile of non-HDL cholesterol levels had 28-fold higher odds for having a MI (95% confidence interval, 7.5-104.1), compared to those in the lowest tertile. Finally, discriminant analysis showed that non-HDL cholesterol (lambda-Wilks=0.68) was the strongest discriminator for MI among all studied risk factors while smoking (lambda-Wilks=0.80) was the strongest discriminator for MI among the non-lipid risk factors.
CONCLUSIONS: Our study suggests that among conventional lipid and non-lipid risk factors non-HDL cholesterol is the best discriminator to predict the presence of MI in individuals under the age of 36 years.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15777546     DOI: 10.1016/j.atherosclerosis.2004.09.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Dominic P Tilden; Segundo Mariz; Gillies O'Bryan-Tear; Julia Bottomley; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians.

Authors:  Jaroslav A Hubacek; Zdena Skodová; Vera Lánská; Vera Adámková
Journal:  Exp Clin Cardiol       Date:  2008

3.  Lipid-modifying therapy in diabetic patients with high plasma non-high-density lipoprotein cholesterol after percutaneous coronary intervention.

Authors:  Kai Xu; Ya-Ling Han; Quan-Min Jing; Shou-Li Wang; Ying-Yan Ma; Bo Luan; Zu-Lu Wang; Dong-Mei Wang
Journal:  Exp Clin Cardiol       Date:  2007

4.  Non-high-density lipoprotein cholesterol predicts nonfatal recurrent myocardial infarction in patients with ST segment elevation myocardial infarction.

Authors:  Ming Gao; Yang Zheng; Weihua Zhang; Yi Cheng; Lin Wang; Ling Qin
Journal:  Lipids Health Dis       Date:  2017-01-23       Impact factor: 3.876

Review 5.  Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target.

Authors:  Michel R Hoenig
Journal:  Vasc Health Risk Manag       Date:  2008

6.  Non-high-density lipoprotein cholesterol is more informative than traditional cholesterol indices in predicting diabetes risk for women with normal glucose tolerance.

Authors:  Lu Liu; Qiu Li; Zhongshang Yuan; Meng Zhao; Xu Zhang; Haiqing Zhang; Dongmei Zheng; Jin Xu; Ling Gao; Qingbo Guan; Jiajun Zhao; Christopher G Proud; Xuemin Wang; Xu Hou
Journal:  J Diabetes Investig       Date:  2018-04-19       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.